30 December 2021 - Celltrion announced on December 30 that it won marketing approval from Health Canada for "Yuflyma", a biosimilar of "Humira", a blockbuster treatment for autoimmune disease developed by Celltrion.

Celltrion has secured marketing licenses for major indications owned by the original drug Humira, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

Read Korea Times article